cabozantinib
exelixis
['atlantis', 'cabozantinib']
atlantis trial: cabozantinib did not show a significant benefit compared to placebo when used in the switch maintenance setting following platinum based chemotherapy #asco22 
Medical oncologist. Clinical researcher focused in GU tumors. Director Institute of Oncology. Associate Professor UCM. Hospital Clinico San Carlos Madrid, Spain